Oncopeptides Launches Real-World MARINA Study for Pepaxti in Germany

Oncopeptides AB ( (SE:ONCO) ) has shared an announcement.

Oncopeptides has launched the MARINA study in Germany to generate real-world evidence on the effectiveness, safety, and treatment patterns of its multiple myeloma drug Pepaxti in combination with dexamethasone. Conducted with iOMEDICO as sponsor and coordinator, the prospective non-interventional study will follow 50 heavily pretreated adult patients with relapsed, refractory multiple myeloma across about 25 sites, using the SYNERGY platform to enable agile site activation.

The trial will assess disease control rate as a primary effectiveness metric, monitor adverse events, examine Pepaxti’s role as a bridging therapy to advanced immunotherapies such as CAR-T cells and bispecific antibodies, and track quality-of-life outcomes. By focusing on routine clinical practice and diverse patient populations, including older and comorbid patients, the study is intended to strengthen Pepaxti’s clinical positioning in late-line settings and provide German hematologists with data to guide real-world prescribing decisions, with first patient enrollment expected in the second quarter of 2026.

The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK3.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.

More about Oncopeptides AB

Oncopeptides AB is a Swedish biotech company focused on developing and commercializing targeted therapies for difficult-to-treat cancers. Using its proprietary Peptide Drug Conjugate and SPiKE technology platforms, the company markets its flagship drug Pepaxti in Europe and has partnership agreements in South Korea, the Middle East, Africa, and other regions, supported by operations across several European countries.

Average Trading Volume: 2,294,121

Technical Sentiment Signal: Sell

Current Market Cap: SEK601.2M

Find detailed analytics on ONCO stock on TipRanks’ Stock Analysis page.